Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia
- PMID: 19253312
- DOI: 10.1002/pd.2217
Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia
Abstract
Objective: This study aimed to analyze the differences of soluble endoglin (sEng) and transforming growth factor-beta1 (TGF-beta1) according to preeclamptic complications and to investigate the correlation between these factors and the clinical symptoms of preeclampsia.
Method: We estimated the levels of sEng and TGF-beta1 in plasma collected in the second trimester at the time of genetic amniocentesis from 60 women who subsequently developed preeclampsia and 124 contemporaneous normotensive women.
Results: sEng levels were higher in cases than in controls, whereas TGF-beta1 levels were lower (P < 0.001). sEng levels, but not TGF-beta1 levels, were higher in cases with severe or preterm delivery than in cases with mild preeclampsia or term delivery (P < 0.001) and were increased in cases destined to deliver a small gestational age neonate (P < 0.001). Moreover, sEng levels, but not TGF-beta1 levels, showed a positive correlation with maximum diastolic and systolic blood pressure (r = 0.57, P < 0.001; and r = 0.33, P < 0.001, respectively) and proteinuria (r = 0.42, P < 0.001).
Conclusion: Early midtrimester plasma levels of sEng are predictive of subsequence occurrence and severity of preeclampsia, in terms of severity of hypertension and proteinuria, prematurity, and association with small for gestational age neonates.
(c) 2009 John Wiley & Sons, Ltd.
Similar articles
-
Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.Obstet Gynecol. 2008 Jun;111(6):1403-9. doi: 10.1097/AOG.0b013e3181719b7a. Obstet Gynecol. 2008. PMID: 18515525
-
Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset.Hypertens Res. 2008 Aug;31(8):1541-8. doi: 10.1291/hypres.31.1541. Hypertens Res. 2008. PMID: 18971528
-
Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia.PLoS One. 2014 May 22;9(5):e97632. doi: 10.1371/journal.pone.0097632. eCollection 2014. PLoS One. 2014. PMID: 24851923 Free PMC article.
-
Review: the enigmatic role of endoglin in the placenta.Placenta. 2014 Feb;35 Suppl:S93-9. doi: 10.1016/j.placenta.2013.10.020. Epub 2013 Nov 8. Placenta. 2014. PMID: 24252708 Review.
-
Soluble endoglin, hypercholesterolemia and endothelial dysfunction.Atherosclerosis. 2015 Dec;243(2):383-8. doi: 10.1016/j.atherosclerosis.2015.10.003. Epub 2015 Oct 8. Atherosclerosis. 2015. PMID: 26520890 Review.
Cited by
-
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction.Sci Rep. 2020 Jul 16;10(1):11848. doi: 10.1038/s41598-020-68842-1. Sci Rep. 2020. PMID: 32678284 Free PMC article.
-
Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy.Case Rep Obstet Gynecol. 2015;2015:123408. doi: 10.1155/2015/123408. Epub 2015 Aug 27. Case Rep Obstet Gynecol. 2015. PMID: 26413360 Free PMC article.
-
Antigen Analysis of Pre-Eclamptic Plasma Antibodies Using Escherichia Coli Proteome Chips.Mol Cell Proteomics. 2018 Aug;17(8):1457-1469. doi: 10.1074/mcp.RA117.000139. Epub 2017 Dec 28. Mol Cell Proteomics. 2018. PMID: 29284593 Free PMC article.
-
Biomarkers and point of care screening approaches for the management of preeclampsia.Commun Med (Lond). 2024 Oct 22;4(1):208. doi: 10.1038/s43856-024-00642-4. Commun Med (Lond). 2024. PMID: 39433973 Free PMC article. Review.
-
TGFβ1, SNAIL2, and PAPP-A Expression in Placenta of Gestational Diabetes Mellitus Patients.J Diabetes Res. 2024 Jul 30;2024:1386469. doi: 10.1155/2024/1386469. eCollection 2024. J Diabetes Res. 2024. PMID: 39109165 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources